louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00381147: Use of Clarithromycin in Mustard-Induced Bronchiolitis
Official title: Phase III, Randomized, Double Blind Study of Low Dose Long Term Clarithromycin Versus Placebo in Treatment of Chronic Pulmonary Lesions Due to Sulfur Mustard
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Bronchiolitis Obliterans
Acute Obliterating Bronchiolitis
Lead sponsor: Baqiyatallah Medical Sciences University
Sponsor class: OTHER
First posted: 2006-09-27
Sex: MALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: We looked for the effectiveness of low-dose long-term prescription of clarithromycin in mustard-induced chronic pulmonary lesions, especially bronchiolitis obliterans


Eligibility criteria: Inclusion Criteria:

* His/her own will to participate
* Documented chemical exposure
* Clinical, spirometric and radiological findings were compatible with BO on High Resolution Computed Tomography (HRCT)

Exclusion Criteria:

* any drug reactions during the trial
* history of sensitivity to macrolides
* diarrhea, gray stool, jaundice, eosinophilia, acute cholestatic hepatitis, pruritis, dark urine, abdominal pain, osteomatosis, depression, taste change, behavioural changes, early fatigue, odynophagia, glossitis , dizziness
* co-adminstration of: terfenadine, theophylline, carbamazepine, ergotamine, dihydroergotamine, warfarin, cisapride, digoxin, triazolam, phenytoin, steroids, any immunosuppressive, any systemic antibiotics
* using drugs that he/she cannot discontinue
* using drugs with potential interaction
* subject will to exit from the trial
* history of lobe resection of lung
* history of exacerbation in the last month prior to the beginning of trial
* continuous need to oxygen
* use of corticosteroids in last week prior to the trial beginning
* Radiographic evidence of pneumonia, active tuberculosis, lung carcinoma, or an infection that necessitated the use of an antibiotic
* exacerbating of subjects
* creatinine srum level more than normal
* increasing ALT, AST levels
* total bilirubin more twice than normal
* subjects who did not use their drugs properly

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: Baqiyatallah Medical Sciences University
Study officials:
affiliation: Research Center of Chemical Injuries, Baqyatallah Medical Sciences University, Tehran, Iran
name: Mostafa Ghanei, Professor
role: STUDY_DIRECTOR
References:
Clinical trial NCT00521547: To Study the Mechanisms of Acupuncture Through Functional Magnetic Resonance Imaging and Peripheral Neurosensory Testing
Official title: Healthy Subject Studies to Assess the Effect of Different Electroacupuncture Parameters on Analgesia, Peripheral Sensory Thresholds and Central Pain Processing.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Keywords: Acupuncture
Analgesia
Functional magnetic resonance imaging (fMRI)
Neuronal Mechanisms
Quantitative Peripheral Sensory Testings
Normal Volunteers
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH)
Sponsor class: NIH
First posted: 2007-08-28
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: Acupuncture may affect nerve functions. This study assesses the effect of acupuncture on both the peripheral and the central nerve systems


Eligibility criteria: Inclusion Criteria:

* Age 18 to 80
* Male and female
* No acupuncture treatment for the past 2 weeks
* No analgesics for the past 2 weeks
* Absence of neuropathic pain states

Exclusion Criteria:

* History of psychological illness
* History of Claustrophobia
* Lack of ability to understand the experimental protocol and to adequately communicate in English
* Pregnancy
* Pending litigation
* History of head trauma
* History of trauma or surgery to lower extremities and pelvic area

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: La Jolla
country: United States
facility: The University of California, San Diego, Medical Center
state: California
Study officials:
affiliation: University of California, San Diego
name: Albert Leung, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02394847: Does Repetitive Electroconvulsive Therapies Affect Propofol Induction Dose ?
Official title: Does Repetitive Electroconvulsive Therapies Affect Propofol Induction Dose?
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Physiatrics
Electroconvulsive Therapy
Keywords: propofol
electroconvulsive therapy
anesthesia
Lead sponsor: Ankara University
Sponsor class: OTHER
First posted: 2015-03-20
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SCREENING

Brief summary: Electroconvulsive therapy has been used for many years for different types of physiatric diseases. General anesthesia is used during the procedure. Different anesthesiologists use different regimens. The duration of seizure is important in this procedure. The investigators evaluated the relationship between the dose of propofol and the number of electroconvulsive therapy and duration of the seizure.


Eligibility criteria: Inclusion Criteria:

* Patients required electroconvulsive therapy for the physiatric disease

Exclusion Criteria:

* Patients refusal

Primary outcomes:
measure: dose of propofol
timeFrame: 10 seconds
Secondary outcomes:
measure: duration of seizure
timeFrame: 10 seconds
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05816447: Patients' Perception of Climate Change and Healthcare
Official title: Patients' Perception of Climate Change and Healthcare - a Cross-section Cohort Study in a Single Institution in Canada
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Perception, Self
Keywords: Environmental sustainability
Anesthesia
Healthcare
Lead sponsor: University of Alberta
Sponsor class: OTHER
First posted: 2023-04-18
Enrollment: 320
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients at the hospital

Brief summary: This study aims to investigate the patients' perception of the negative impact of the healthcare industry on climate change, their attitude of climate change and their health, and their view of seeing a change in the healthcare system to reduce climate change.

Detailed description: Climate change is a threat to human health which in turn increases burden on our healthcare system. Healthcare is also a very polluted industry which has a huge contribution to climate change. It is important to take action and the intergovernmental panel on climate change (IPCC) has put out a warning of 'Code Red for Humanity' urging immediate action from all of humanity to combat climate change. This is important because if no action is taken, irreversible damage might result on our planet which will become a challenge in terms of living conditions, food source, and health.

Therefore, this study aims to investigate the patients' perception of the negative impact of the healthcare industry on climate change, their attitude of climate change and their health, and their view of seeing a change in the healthcare system to reduce climate change. This will produce data on the knowledge gap in our patients and thereby empower them to request and target our education for patients, and in turn encourage the healthcare system to reflect on their environmental sustainable practices.

Eligibility criteria: Inclusion Criteria:

* All adult patients \> age of 18 years old
* Willing and able to read/listen and understand English, on the hospital ward ie. Not Emergency Department

Exclusion Criteria:

* Patient refusal
* Patients are unable to consent
* Confusion or disorientated in time, space and person

Primary outcomes:
measure: Patients' awareness of climate change from the healthcare industry
timeFrame: Baseline
Secondary outcomes:
measure: To evaluate their attitude on climate change, view of change in the healthcare system to reduce climate change
timeFrame: Baseline
Other outcomes:
Locations:
city: Edmonton
country: Canada
facility: University of Alberta Hospital
state: Alberta
Study officials:
References:
Clinical trial NCT04201847: Follicular Fluid Fetuins in in Vitro Fertilization
Official title: Follicular Fetuin A and Fetin B Levels Are Associated With Clinical Pregnancy and Live Birth Rates in IVF Cycles
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Infertility
Infertility, Female
Lead sponsor: Samsun Education and Research Hospital
Sponsor class: OTHER
First posted: 2019-12-17
Enrollment: 96
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: This study aims to investigate whether follicular fluid concentrations of fetuin A and fetuin B are associated with the clinical pregnancy and live birth rates in in vitro fertilization (IVF) cycles.Twenty-nine women with poor ovarian reserve (poor responders) and 33 women with polycystic ovary syndrome (hyper responders) who consecutively underwent IVF at a private hospital between May 2018 and February 2019.Fetuin A and fetuin B in follicular fluid were significantly lower in women who had clinical pregnancy than women who had no clinical pregnancy (p=0.001 for both)


Eligibility criteria: Inclusion Criteria:

Poor ovarian reserve patients and patient with polycystic ovary syndrome

Exclusion Criteria:

Normoresponders

Primary outcomes:
measure: he primary outcome of this study is to measure the follicüler fluid concentrations of fetuin A and fetuin B in IVF cycles. Follicular fluid Fetuin A and Fetuin B will be measured during oosit pick up in IVF cycles.
timeFrame: 4 weeks
measure: The secondary goal of this study is to whether follicular fluid concentrations of fetuin A and fetuin B are associated with clinical pregnancy and live birth rates in IVF cycles.
timeFrame: 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Samsun
country: Turkey
facility: Samettin Çelik
Study officials:
References:
Clinical trial NCT00490347: VentrAssistTM LVAD as a Bridge to Cardiac Transplantation - Feasibility Trial
Official title: Evaluation of the VentrAssistTM Left Ventricular Assist Device as a Bridge to Cardiac Transplantation - Feasibility Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: End-Stage Heart Failure
Cardiomyopathies
Keywords: VentrAssistTM
LVAD
End-stage heart failure
Cardiomyopathy
Lead sponsor: Ventracor
Sponsor class: INDUSTRY
Collaborators: name: International Center for Health Outcomes and Innovation Research
First posted: 2007-06-22
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this trial is to determine the safety and feasibility of the VentrAssist LVAD in providing circulatory support for patients who require an LVAD as a bridge to cardiac transplantation.


Eligibility criteria: Inclusion Criteria (The following are general criteria; more specific criteria are included in the study protocol):

* Approved and listed for cardiac transplantation.
* Patient for whom LVAD implantation is planned as a clinically indicated bridge to cardiac transplantation.

Exclusion Criteria(The following are general criteria; more specific criteria are included in the study protocol):

* Presence of heart conditions that would contraindicate LVAD implantation by adversely affecting patient survival or LVAD function.
* Primary coagulopathy or platelet disorder; contraindication to anticoagulant or anti-platelet agents.
* Presence of any mechanical circulatory support other than intra-aortic balloon pump.
* Therapy with an investigational intervention at the time of screening.

Primary outcomes:
measure: Survival
Secondary outcomes:
measure: Quality of life
measure: Functional status
measure: Neurocognitive function
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: University of Maryland Medical Center - Baltimore
state: Maryland
city: Minneapolis
country: United States
facility: University of Minnesota Medical Center - Fairview
state: Minnesota
city: New York
country: United States
facility: New York Presbyterian Medical Center - Columbia
state: New York
city: Cleveland
country: United States
facility: Cleveland Clinic Foundation
state: Ohio
city: Pittsburgh
country: United States
facility: University of Pittsburgh Medical Center
state: Pennsylvania
Study officials:
References:
Clinical trial NCT02775747: PRP Gel in Wound Closure in Recurrent CS
Official title: Platelet Rich Plasma Gel in Wound Closure in Recurrent Cesarean Section:Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Previous Incision
Scar; Previous Cesarean Section
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2016-05-18
Enrollment: 128
Sex: FEMALE
Minimum age (years): 25
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: There is limited application of the use of PRP in obstetrics, therefore there is a need for assessment if it is efficacy in improving skin wound healing in cesarean section.

Detailed description: This study aims to assess the efficacy of injection of platelet rich plasma into the wound of recurrent cesarean section for improving wound healing and enhancing the shape of the wound in women undergoing cesarean section.

Eligibility criteria: Inclusion Criteria:

* elective cesarean section
* Body mass index 18:25
* Hemoglobin more than 10.5 g/d
* Albumin within normal more than or equal 3.5 g/d

Exclusion Criteria:

* medical disorders(Diabetes mellitus,heart disease,hypertension,systemic lupus erythematosus)
* high risk pregnancy as (placenta previa,placenta accreta)
* patient on corticosteroids medication
* primigravida subjected cesarean section
* complicated cesarean section (increased operation time,blood transfusion, drain, scrubbing of multiple surgeons)
* cesarean section due to chorioaminionitis
* postoperative complication such as:postpartum hemorrhage, paralytic ileus, sever distention..) will be dropped out from the study

Primary outcomes:
measure: Efficacy of PRP in Wound healing in cesarean section by 100 mm visual analog scale
timeFrame: one month
Secondary outcomes:
measure: Assessment of the Cosmetic results of the wound by Modified Vancouver scar scale
timeFrame: one month
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Rasha
state: Al Qahirah
Study officials:
affiliation: Ain Shams University
name: RASHA DR MEDHAT, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Ain Shams University
name: Rasha M Abdul-hady, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00214747: An Imaging Trial of the Distribution of Topical Gel Formulations in the Human Vagina
Official title: An Imaging Trial of the Distribution of Topical Gel Formulations in the Human Vagina: Candidate Formulations
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: HIV Infections
Keywords: HIV Seronegativity
HIV
Lead sponsor: Biosyn
Sponsor class: INDUSTRY
Collaborators: name: National Institute of Allergy and Infectious Diseases (NIAID)
First posted: 2005-09-22
Enrollment: 6
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This study is designed to assess the distribution and spread of four different vehicle formulations in the vagina. In-vivo data will be obtained regarding each vehicle formulation at various time points after insertion of the gel into the vagina.


Eligibility criteria: Inclusion Criteria:

* 18 to 45 year old women
* non-pregnant
* healthy

Exclusion Criteria:

* abnormal finding on pelvic exam
* pregnant or breastfeeding
* allergy to intravaginal products
* history of claustrophobia

Primary outcomes:
measure: MRI evaluation of gel formulation distribution in vagina
measure: Total linear distance in mm covered by gel
measure: Surface area actually covered by gel (mm)
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Rreproductive Research Unit, U of Penn Medical Center
state: Pennsylvania
Study officials:
affiliation: University of Pennsylvania
name: Kurt Barnhart, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04652947: MR Quality + Diagnostic Performance for CHC Diagnosis - Gadoxetic Acid, Gadoteric Acid and P03277 Comparison
Official title: MR Quality + Diagnostic Performance for CHC Diagnosis - Gadoxetic Acid, Gadoteric Acid and P03277 Comparison
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hepatocellular Carcinoma
Lead sponsor: University Hospital, Angers
Sponsor class: OTHER_GOV
First posted: 2020-12-03
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients followed for hepatopathy

Brief summary: Compare diagnostic MRI performance of gadoteric acid, gadoxetic acid and P03277 for suspected CHC nodules less than 3 cm, using LIRADS criteria


Eligibility criteria: Inclusion Criteria:

* Patients who had all three MRI scans as part of the diagnosis of the same suspected CHC lesion(s)
* Reference diagnosis obtained for suspected CHC nodules by a diagnostic algorithm taking into account histology, imaging and follow-up

Exclusion Criteria:

* Delay between first MRI and 3rd MRI greater than 3 months

Primary outcomes:
measure: compare diagnostic MRI performance of gadoteric acid, gadoxetic acid and P03277 for suspected CHC nodules
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01092247: The Effect of Ketogenic Diet on Malignant Tumors- Recurrence and Progress
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Malignant Tumors
Keywords: Patients with malignant tumors
Lead sponsor: Tel-Aviv Sourasky Medical Center
Sponsor class: OTHER_GOV
Collaborators: name: Nutricia Liverpool
First posted: 2010-03-24
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL

Brief summary: The aim of the study is, to study the efficacy of the ketogenic diet in delaying or preventing recurrence and tumor growth progression of patients who have been previously treated by concomitant chemoradiotherapy (6 months) for high-grade glial tumors.

It will be an open-label trial of nutritional intervention for up to 1 year. An interim analysis of the data will be carried out to assess safety, compliance and efficacy of the diet. This will be reviewed by both SHS and the Clinical trial team.


Eligibility criteria: Inclusion criteria:

1. Consenting adults aged ≥ 18 years.
2. Recurrent or progressive high grade glioma after failure of at least one line of standard oncological treatment.
3. Gliomatosis cerebri, including patients declining radiation treatment.

Exclusion criteria:

1. Patients with malignant tumors who are receiving treatment at the time of the recruitment.
2. Early termination - patients who will wish to stop their participation in the trial will discontinue the ketogenic diet and return to their usual diet.

Primary outcomes:
measure: To study the effect of the ketogenic diet on tumor growth progression and longevity in patients with Malignant glioblastoma.
Secondary outcomes:
measure: Quality of life
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02541747: Assessments in Stress and Quality of Sleep/Life in Night-shift Nurses and Doctors
Official title: Assessments in Stress and Quality of Sleep/Life in Night-shift Nurses and Doctors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Shift-Work Sleep Disorder
Lead sponsor: Taichung Veterans General Hospital
Sponsor class: OTHER
First posted: 2015-09-04
Enrollment: 77
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to evaluate the effects of aroma massage to sleep quality of the nurses and staff during night shift.

Detailed description: Night shift increases physical and psychological pressure, and even affects their sleep quality. This study aims to evaluate the effects of aroma massage to sleep quality of the nurses during night shift after life-style modification and/or aroma massage. The investigators adopt a Randomized Controlled Trial (RCT) in this study. The investigators expect aroma massage would improve the sleep quality during night shift.

Eligibility criteria: Inclusion Criteria:

* Shift-Work Nurses and Staff

Exclusion Criteria:

* Diabetes mellitus, cardiovascular disease and psychological disorders

Primary outcomes:
measure: brain-derived neurotrophic factor
timeFrame: 4 weeks
Secondary outcomes:
measure: Pittsburgh sleep quality index (PSQI)
timeFrame: 4 weeks
measure: Depression score ( Zung's Self-Reported Depression Scale)
timeFrame: 4 weeks
measure: Anxiety score (Beck Anxiety Inventory)
timeFrame: 4 weeks
measure: Heart rate variability
timeFrame: 4 weeks
measure: Metabolic syndrome (NCEP)
timeFrame: 4 weeks
measure: VCAM-1
timeFrame: 4 weeks
measure: Irisin
timeFrame: 4 weeks
measure: circadian rhythm
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Taichang
country: Taiwan
facility: Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital
Study officials:
affiliation: Taichung Veterans General Hospital
name: Wayne HH Sheu, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: